AKBA - Akebia Therapeutics, Inc.
IEX Last Trade
1.955
0.015 0.767%
Share volume: 67,767
Last Updated: Fri 27 Dec 2024 08:29:43 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.25%
PREVIOUS CLOSE
CHG
CHG%
$1.94
0.02
0.77%
Fundamental analysis
26%
Profitability
25%
Dept financing
25%
Liquidity
21%
Performance
28%
Performance
5 Days
4.32%
1 Month
-6.31%
3 Months
45.11%
6 Months
94.95%
1 Year
60.83%
2 Year
368.90%
Key data
Stock price
$1.96
DAY RANGE
$1.91 - $1.96
52 WEEK RANGE
$0.93 - $2.48
52 WEEK CHANGE
$55.65
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: John P. Butler
Region: US
Website: akebia.com
Employees: 430
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: akebia.com
Employees: 430
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Akebia Therapeutics, Inc. focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients on dialysis.
Recent news